Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $16.0552W HIGH $35.34
Volume
136.15 K
Value Traded
11.91 M
Short % Float
6.35%
+0.49%Week
0%1 Month
+46.78%3 Month
+106.54%6 Month
-14.18%5 Year
-81.46%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
322.04 M
EPS (TTM)
-3.48
P/E Ratio
-
Ent. Value
353.10 M
Total Shares
9.19 M
Float Shares
4.88 M
Insiders
46.90%
Institutions
18.10%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
SMTI Catalyst Timeline
Dated clinical, regulatory and corporate events for Sanara MedTech Inc.
Past FDA Catalysts and PDUFA Decisions
How SMTI actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Sanara MedTech Inc. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every SMTI program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Yon Seth DDirector, Officer (Chief Executive Officer) | Disposition | -3,852 109,546 held | $21.06 | 05/15/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in SMTI
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Opaleye Management Inc. | 1 % | 7.01 M | 225.00 K |
SMTI Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How SMTI ranks across every disease it competes in
Competitive Position is a premium feature
See how SMTI ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialSMTI News
SMTISanara MedTech Inc. Reports Second Quarter 2026 Financial Results (Unaudited)
Sanara MedTech Inc. reported a 9% increase in net revenue for Q2 2026, totaling $28.1 million, driven by growth in soft tissue repair products. The company also announced a planned acquisition by MIMEDX, which aims to enhance its surgical product offerings. Despite these positive developments, Sanara experienced a net loss from continuing operations of $0.4 million due to rising operating expenses and interest costs.
Read more →SMTI▲ +12.6%on this news
MIMEDX to Acquire Sanara MedTech
MIMEDX has announced its acquisition of Sanara MedTech in a cash and stock transaction valued at approximately $350 million. This merger aims to enhance MIMEDX's surgical portfolio and expand its market presence. The deal is expected to be immediately accretive to revenue growth and result in significant cost synergies, with a projected total revenue exceeding $400 million by 2027.
Read more →SMTI▲ +13.4%on this news
Sanara MedTech Inc. Reports First Quarter 2026 Financial Results (Unaudited)
Sanara MedTech Inc. reported a 19% increase in net revenue for Q1 2026, reaching $27.8 million, driven by strong sales in soft tissue repair products. The company achieved net profitability of $0.04 per diluted share, despite a rise in operating expenses. Looking ahead, Sanara maintains its full-year revenue growth guidance of 13% to 17%.
Read more →SMTI▲ +5.2%on this news· ran to +18% by day 3
Sanara MedTech Inc. to Report First Quarter 2026 Financial Results on May 12, 2026
Sanara MedTech Inc. will report its first quarter 2026 financial results on May 12, 2026, before the U.S. markets open. A conference call will be held at 8:00 a.m. ET to discuss the results and include a Q&A session. The company focuses on innovative surgical solutions to enhance clinical outcomes and reduce costs.
Read more →SMTI▲ +6.5%on this news· ran to +20% by day 3shared move
Sanara MedTech, Inc. Investigated by the Portnoy Law Firm
Sanara MedTech, Inc. is facing an investigation initiated by the Portnoy Law Firm over potential securities fraud related to the company's discontinuation of its Tissue Health Plus (THP) program. Following this announcement and the subsequent release of financial results, which reported a net loss from discontinued operations of $31.2 million, the company's stock plummeted by 24.7%. The law firm invites affected investors to participate in a class action to seek recovery for their losses. Concerns about corporate governance and financial management are front and center in this developing situation.
Read more →SMTISanara MedTech Inc. Reports Fourth Quarter (Unaudited) and Full Year 2025 Financial Results; Reaffirmed Full Year 2026 Financial Guidance
Sanara MedTech Inc. reported a 19% increase in net revenue for 2025, reaching $103.1 million. The company also achieved an adjusted EBITDA of $17.0 million, up from $9.1 million in 2024. Despite a net loss from continuing operations, Sanara reaffirmed its financial guidance for 2026, projecting revenue growth of 13% to 17%. The company continues to focus on expanding its surgical product offerings.
Read more →SMTISanara MedTech Inc. Announces Publication of Peer-Reviewed Study Evaluating the Economic and Clinical Value of CellerateRX Surgical Powder in the Management of Spine Surgery Wounds
Sanara MedTech Inc. announced the publication of a peer-reviewed study in the Journal of Medical Economics, highlighting the benefits of CellerateRX Surgical Powder as an adjunct treatment for high-risk spinal surgery patients. The study showed that using CellerateRX resulted in substantial cost savings and improvements in health outcomes compared to standard care alone. Specifically, it demonstrated a cost saving of $3,852 per patient and improved quality-adjusted life years (QALYs), supporting CellerateRX as a valuable addition to surgical wound management. Sanara plans to raise awareness of this study in the marketplace to promote its clinical effectiveness.
Read more →SMTISanara MedTech Inc. to Report Fourth Quarter and Full Year 2025 Financial Results on March 24, 2026
Sanara MedTech Inc. will report its fourth quarter and full year 2025 financial results on March 24, 2026. A conference call is scheduled for the same day to discuss the results and include a Q&A session. The company emphasizes its commitment to developing transformative technologies in the surgical market.
Read more →SMTISanara MedTech Inc. to Participate in the TD Cowen 46th Annual Health Care Conference on March 3rd
Sanara MedTech Inc. announced its participation in the TD Cowen 46th Annual Health Care Conference, scheduled for March 3, 2026. The company will present its innovative surgical technologies aimed at improving clinical outcomes and reducing costs. Presentation materials will be available on their investor relations website, along with a live audio webcast.
Read more →SMTISanara MedTech Inc. Reports Unaudited Preliminary Financial Results for the Fourth Quarter and Full Year 2025; Introduces Full Year 2026 Financial Guidance
Sanara MedTech Inc. reported preliminary financial results for Q4 and full year 2025, showing a 19% increase in net revenue. The company also provided guidance for 2026, expecting revenue growth of 13% to 17%, driven by its soft tissue products. A new contract with Vizient enhances market access for its offerings.
Read more →SMTISanara MedTech Inc. Receives Innovative Technology Contract from Vizient for BIASURGE Advanced Surgical Solution
Sanara MedTech Inc. has been awarded an Innovative Technology contract by Vizient Inc. for its BIASURGE Advanced Surgical Solution. This recognition is based on the product's recommendation by hospital experts, highlighting its potential to enhance surgical outcomes and patient safety. The contract, effective January 1, 2026, allows access to BIASURGE at negotiated pricing for Vizient's extensive healthcare network. The BIASURGE solution offers a no-rinse irrigation option, enhancing the efficiency of surgical cleansing while providing antimicrobial protection.
Read more →SMTISanara MedTech Inc. and Biomimetic Innovations Provide Update on OsStic™
Sanara MedTech Inc. and Biomimetic Innovations have announced progress on their OsStic™ bio-adhesive, set for U.S. market launch in Q1 2027. The FDA granted OsStic Breakthrough Device Designation, recognizing its potential for treating peri-articular fractures. The product boasts superior bonding capabilities and is expected to address critical needs in orthopedic surgery.
Read more →SMTI▼ -8.8%on this news
Sanara MedTech to Participate in the Piper Sandler 37th Annual Healthcare Conference on December 3rd
Sanara MedTech Inc. will participate in the Piper Sandler 37th Annual Healthcare Conference from December 2-4, 2025. Management is scheduled to present on December 3 at 9:30 a.m. ET. The presentation materials will be available on the company's investor relations website, along with a live audio webcast.
Read more →SMTI▼ -24.7%on this news
Sanara MedTech Inc. Reports Third Quarter 2025 Financial Results (Unaudited)
Sanara MedTech Inc. reported a 22% increase in net revenue for Q3 2025, reaching $26.3 million, driven by strong sales of surgical soft tissue products. The company also noted improvements in profitability, with adjusted EBITDA rising to $4.9 million. However, it faced a significant net loss of $30.4 million due to discontinued operations and an asset impairment charge. The company has ceased operations of its THP segment to focus on its core surgical business.
Read more →SMTI▼ -24.7%on this newsshared move
Sanara MedTech Inc. Announces Strategic Realignment to Focus on Surgical Business
Sanara MedTech Inc. has completed an evaluation of its Tissue Health Plus segment, resulting in a strategic realignment to focus on its surgical business. The company will discontinue THP operations to improve efficiency and reallocate resources. This decision is based on the surgical business's strong revenue growth and potential for sustainable value creation.
Read more →SMTISanara MedTech to Report Third Quarter 2025 Financial Results on November 12, 2025
Sanara MedTech Inc. announced plans to report its third quarter 2025 financial results on November 12, 2025, before the U.S. markets open. The company will hold a conference call and webcast on the same day to discuss the outcomes and answer questions. Sanara MedTech specializes in medical technologies aimed at improving clinical results and lowering healthcare costs in surgical and wound care markets.
Read more →SMTISanara MedTech Inc. Announces Chief Executive Officer Transition
Sanara MedTech Inc. has announced the appointment of Seth Yon as President and CEO, effective September 15, 2025. He succeeds Ron Nixon, who will continue as Executive Chairman. The Board believes Yon's leadership will drive the company's growth and success in the medical technology sector. Yon has been with Sanara since 2018 and has played a key role in its commercial strategy.
Read more →SMTISanara MedTech Inc. to Present at the Cantor Global Healthcare Conference on September 3, 2025
Sanara MedTech Inc. announced its participation in the Cantor Global Healthcare Conference from September 2-5, 2025. The management will present during a fireside chat on September 3 at 2:45 p.m. ET. Presentation materials will be available on the company's investor relations website, along with a live audio webcast.
Read more →SMTI▲ +16.2%on this news
Sanara MedTech Inc. Reports Second Quarter 2025 Financial Results (Unaudited)
Sanara MedTech Inc. reported a 28% year-over-year increase in net revenue for Q2 2025, totaling $25.8 million. The company also improved its adjusted EBITDA to $2.7 million compared to $0.6 million in the same quarter last year. However, the net loss for the first half of 2025 increased slightly to $5.5 million. Additionally, the company announced it is evaluating strategic alternatives for its Tissue Health Plus subsidiary due to ongoing financial challenges.
Read more →About Sanara MedTech Inc.
Headquarters1200 SUMMIT AVE, FORT WORTH, TX, 76102
BIOPHARMAWATCH ELITE PLUS
Trade the next SMTI catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime